Teen With Dyspnea After Chest Wall Trauma

Poll

X-rays offer no clue to the cause of dyspnea in this teen who cannot take a deep breath after crashed on his bicycle. Watch the short video, read the clues, and make your diagnosis.

This 17-year-old is unable to take a deep breath after sustaining chest wall trauma during a bike crash. Now, in the ED, he is afebrile; heart rate: 69 beats/min; respiratory rate, 55 breaths/min; BP, 126/87 mmHG; SpO2, 99% on nonrebreather mask. He is otherwise healthy and takes no medications. The initial radiograph was read as normal by the radiologist.

What do you suspect is the cause of the dyspnea?

A. Pneumothorax
B. Rib fracture
C. Clavicle fracture
D. Hemothorax
E. Brachial plexus/phrenic nerve injury
F. Commotio cordis
G. Myocardial contusion
Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes / Image credit: ©Argus/AdobeStock

FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes

Sydney Jennings
December 23rd 2024
Article

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

FDA Adds Black Box Warning to Fezolinetant Label, Advising of Rare but Serious Liver Injury / image credit ©Jerome/stock.adobe.com

FDA Adds Black Box Warning to Fezolinetant Label, Advising of Rare but Serious Liver Injury

Grace Halsey
December 23rd 2024
Article

The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Sydney Jennings
October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Smartphone App Shows Promise for Managing Hypertension in Observational Study / Image credit: ©ra2 studio/AdobeStock

Smartphone App Shows Promise for Managing Hypertension in Observational Study

Sydney Jennings
December 20th 2024
Article

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.

Crinecerfont for Congenital Adrenal Hyperplasia Now Commercially Available, Neurocrine Biosciences Announces / image credit courtesy of Neurocrine Biosciences

Crinecerfont for Congenital Adrenal Hyperplasia Now Commercially Available, Neurocrine Biosciences Announces

Grace Halsey
December 20th 2024
Article

The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.

© 2024 MJH Life Sciences

All rights reserved.